| Revenue growth | FY26 revenue dropped ~12% YoY due to industry-wide pricing erosion. |
|---|---|
| Margins | Gross margins recovering in Q4; merger expected to add 1-2% EBITDA. |
| Order book | Multiple orders for Exblifep in Europe; 4x Q-on-Q improvement. |
| Demand visibility | Stability seen in Q4; growth expected from non-regulated markets (Africa/Asia). |
| Management confidence | High on long-term anti-infective platform and Enmetazobactam lifetime value. |
Growth
FY26 revenue fell to ₹811cr from ₹922cr (FY25). Q4 revenue stable at ₹238cr YoY; EBITDA reached ₹42.3cr.
Outlook
Targeting 10-15% growth for FY27. ₹50cr capex for fill-finish/Cefiderocol facility. 7ACA project commissioning in Q1 2027.
Risks
Global antibiotic industry facing significant pricing/volume pressure, geopolitical instability, and supply chain cost volatility.
Earnings Call filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.